Based on your analysis of the benefits and costs of routine donor screening for ALT-GPT to reduce the incidence of post-transfusion non-A, non-B hepatitis in your blood services region, what action would you recommend on this matter?
D000410:Alanine Transaminase / Q000097:blood*; D001782:Blood Donors / Q000523:psychology; D001803:Blood Transfusion / Q000191:economics; D002353:Carrier State / Q000175:diagnosis; D003362:Cost-Benefit Analysis; D006526:Hepatitis C / Q000209:etiology* / Q000635:transmission; D006525:Hepatitis, Viral, Human / Q000209:etiology*; D006801:Humans; D012306:Risk; D012959:Socioeconomic Factors; D065227:Transfusion Reaction; D014836:Volition
D000410:Alanine Transaminase